Sequential PD-1 Antibody and Pegylated Interferon Therapy for Nucleos(t)Ide Analogue-suppressed Chronic Hepatitis B

Prior treatment

• 4.Patients received interferon therapy within 6 months;
• 5.Patients received immunosuppressive therapy or other therapy influenced study within 6 months;
• 9.Alcohol or drug abuse/dependence;

Other illness

• 3.History of or suspicion of hepatocellular carcinoma
• 7.Hepatitis A, hepatitis C, hepatitis D, HIV infection or other active infections;
• 8.Presence of severe uncontrolled diseases of respiratory, cardiovascular or other organ systems;
• 10.Other conditions rendering subjects ineligible for enrollment, including but not limited to absolute contraindications to interferon therapy, known hypersensitivity to any study drug or their excipients, and anticipated poor compliance with treatment and follow-up procedures.

Lab values

• 2.platelet count \< 90×10\^9/L, WBC count \< 3.0×10\^9/L, ALT /AST\> ULN (40U/L), total bilirubin \> 2ULN;

Other

• 1\. Cirrhosis;
• 6.Pregnancy

• 1\. Aged 18-55 years;
• 2.Chronic hepatitis B patients with clear diagnosis of hematology, etiology and clinical (for example: HBsAg positive for more than 6 months);
• 3\. Treatment with NAs(ETV, TDF or TAF)at least 1 years and continue NAs therapy during screening;
• 4.Patients with HBV DNA negative, HBeAg negative, HBsAg quantification ≤ 500IU/ml .